MX2017003014A - Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. - Google Patents
Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.Info
- Publication number
- MX2017003014A MX2017003014A MX2017003014A MX2017003014A MX2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- beta
- alpha
- humanized anti
- disclosed
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se describen anticuerpos y fragmentos de anticuerpos humanizados que se unen a la avb5. También se describen métodos de uso de los anticuerpos y fragmentos de anticuerpos descritos para tratar o prevenir enfermedades mediadas por la avb5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049987P | 2014-09-12 | 2014-09-12 | |
PCT/US2015/049746 WO2016040839A1 (en) | 2014-09-12 | 2015-09-11 | Humanized anti-alpha v beta 5 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017003014A true MX2017003014A (es) | 2017-05-30 |
Family
ID=54150752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003014A MX2017003014A (es) | 2014-09-12 | 2015-09-11 | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170362324A1 (es) |
EP (1) | EP3191519A1 (es) |
JP (1) | JP2017534252A (es) |
CN (1) | CN107001469A (es) |
AU (1) | AU2015314809A1 (es) |
CA (1) | CA2959772A1 (es) |
MA (1) | MA40536A (es) |
MX (1) | MX2017003014A (es) |
WO (1) | WO2016040839A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101752515B1 (ko) * | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
CN109862913B (zh) | 2016-09-29 | 2023-09-05 | 加利福尼亚大学董事会 | 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053041B1 (en) * | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
PL330241A1 (en) * | 1996-05-31 | 1999-05-10 | Scripps Research Inst | Methods of and compositions useful in inhibiting angiogenesis |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
DK1734996T3 (da) * | 2004-04-02 | 2013-06-10 | Univ California | Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin |
CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB-特异性抗体及其使用方法 |
KR101752515B1 (ko) * | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
WO2012027745A1 (en) * | 2010-08-27 | 2012-03-01 | University Of Miami | Treatment of renal diseases |
CA2889475A1 (en) * | 2012-10-30 | 2014-05-08 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
-
2015
- 2015-09-11 CN CN201580055534.7A patent/CN107001469A/zh active Pending
- 2015-09-11 CA CA2959772A patent/CA2959772A1/en not_active Abandoned
- 2015-09-11 US US15/510,422 patent/US20170362324A1/en not_active Abandoned
- 2015-09-11 JP JP2017513632A patent/JP2017534252A/ja active Pending
- 2015-09-11 MA MA040536A patent/MA40536A/fr unknown
- 2015-09-11 WO PCT/US2015/049746 patent/WO2016040839A1/en active Application Filing
- 2015-09-11 MX MX2017003014A patent/MX2017003014A/es unknown
- 2015-09-11 EP EP15767053.0A patent/EP3191519A1/en not_active Withdrawn
- 2015-09-11 AU AU2015314809A patent/AU2015314809A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2017534252A (ja) | 2017-11-24 |
MA40536A (fr) | 2016-03-17 |
WO2016040839A1 (en) | 2016-03-17 |
AU2015314809A1 (en) | 2017-03-16 |
CN107001469A (zh) | 2017-08-01 |
CA2959772A1 (en) | 2016-03-17 |
US20170362324A1 (en) | 2017-12-21 |
EP3191519A1 (en) | 2017-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ738008A (en) | Tigit-binding agents and uses thereof | |
SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
MX2021003704A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
PH12018501177A1 (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
MX2015011670A (es) | Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5. | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
PH12017501522B1 (en) | Antibodies to tau and uses thereof | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
WO2014143739A3 (en) | Anti-alpha v beta 6 antibodies and uses thereof | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
WO2014144616A3 (en) | Anti-alpha v beta 5 antibodies and uses thereof |